Chippenham, UK-based Vectura says it has now successfully concluded two paediatric studies to support the potential use of asthma drug/device combo VR647.
US regulators have given UK-based Vectura a green light to carry out a Phase I clinical trial of VR647, a drug/device combination being developed for paediatric asthma.